Preview

Real-World Data & Evidence

Advanced search

Real-world evidence market: key players and key segments

https://doi.org/10.37489/2782-3784-myrwd-11

Abstract

Real-world data (RWD) and real-world evidence (RWE) are a valuable resource in the healthcare system. They may be necessary for administrators (to create and improve algorithms for treating patients with various nosologies), physicians (to make a better clinical decision in favor of the patient) and directly to patients and their relatives (to better understand the treatment process). The creators of this data are also the physicians, patients and health care organizations. To process such a volume of data, specialized specialists are needed — mathematicians, data specialists, biostatistics, which in turn generates a service sector in the field of RWD/RWE. Depending on the component, the market is segmented into datasets and services. In 2020, the services segment held a large share — 58.8% of the global RWE solutions market. The market for these services and the data itself is growing every year and is projected to reach 2.3 billion US dollars by 2026.

About the Authors

A. R. Kasimova
R.R. Vreden Russian Research Institute of Traumatology and Orthopedicsdisabled
Russian Federation

Saint Petersburg


Competing Interests:

Авторы декларируют отсутствие конфликта интересов.



A. S. Kolbin
FSBEI HE I.P. Pavlov SPbSMU MOH Russia
Russian Federation

Saint Petersburg


Competing Interests:

Авторы декларируют отсутствие конфликта интересов.



References

1. Dang A, Kaur K. Comparative effectiveness research and its utility in In-clinic practice. Perspect. Clin. Res. 2016;7(1):9–14. doi: 10.4103/2229–3485.173780

2. Eichler HG, Abadie E, Breckenridge A et al. Bridging the efficacy — effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506. https://doi.org/10.1038/nrd3501.

3. O’Sullivan AK, Thompson D, Drummond MF. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health J.Int. Soc. Pharmacoeconomics Outcomes Res. 2005;8(1):67–79. doi: 10.1111/j.1524–4733.2005.03065.x

4. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health J.Int. Soc. Pharmacoeconomics Outcomes Res. 2007;10(5):326–35. doi: 10.1111/j.1524–4733.2007.00186.x

5. ICPE Annual Conference-pharmacoepi.org — International Society for Pharmacoepidemiology. https://www.pharmacoepi.org/meetings/annual-conference/ (просмотрено 28 февраля 2022 г.).

6. Market Research report: Real World Evidence/RWE Solutions Market by Component Impact — Global Forecast to 2026. https://www.marketsandmarkets.com/ (просмотрено 28 февраля 2022 г.).


Review

For citations:


Kasimova A.R., Kolbin A.S. Real-world evidence market: key players and key segments. Real-World Data & Evidence. 2022;2(1):40-43. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-11

Views: 169


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2782-3784 (Online)